Q2 2019 13F Holders as of 30 Jun 2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
226M
-
Number of holders
-
94
-
Total 13F shares, excl. options
-
68.9M
-
Shares change
-
+4.02M
-
Total reported value, excl. options
-
$1.69B
-
Value change
-
+$152M
-
Put/Call ratio
-
0.74
-
Number of buys
-
62
-
Number of sells
-
-32
-
Price
-
$26.85
Significant Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO) as of Q2 2019
111 filings reported holding ALLO - Allogene Therapeutics, Inc. - Common Stock as of Q2 2019.
Allogene Therapeutics, Inc. - Common Stock (ALLO) has 94 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 68.9M shares
of 226M outstanding shares and own 30.45% of the company stock.
Largest 10 shareholders include TPG Group Holdings (SBS) Advisors, Inc. (21.2M shares), VV Manager LLC (5.88M shares), FMR LLC (5.63M shares), Capital Research Global Investors (5.27M shares), Capital International Investors (3.94M shares), BlackRock Inc. (3.56M shares), VANGUARD GROUP INC (3.44M shares), Capital World Investors (2.77M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.52M shares), and STATE STREET CORP (1.6M shares).
This table shows the top 94 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.